Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial

Theo M. de Witte*, Anne Hagemeijer, Stefan Suciu, Amin Belhabri, Michel Delforge, Guido Kobbe, Dominik Selleslag, Harry C. Schouten, Augustin Ferrant, Harald Biersack, Sergio Amadori, Petra Muus, Joop H. Jansen, Eva Hellstrom-Lindberg, Tibor Kovacsovics, Pierre Wijermans, Gert Jan Ossenkoppele, Alois Gratwohl, Jean-Pierre Marie, Roel Willemze

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1754-1761
JournalHaematologica-the Hematology Journal
Volume95
Issue number10
DOIs
Publication statusPublished - Oct 2010

Keywords

  • myelodysplastic syndromes
  • secondary acute myeloid leukemia
  • cytogenetic characteristics
  • allogeneic stem cell transplantation
  • autologous stem cell transplantation
  • intensive chemotherapy

Cite this